摘要
目的探讨马来酸吡咯替尼治疗人类表皮生长因子受体2(HER2)阳性晚期乳腺癌伴肝转移的临床疗效。方法选取2017年4月至2019年4月河北大学附属医院收治的HER2阳性晚期乳腺癌病人1例,先行多西他赛+卡铂+曲妥珠单抗(TCbH)方案6个周期,后再行卡铂+曲妥珠单抗(CbH)2个周期,病情进展(新发、转移)后再予以马来酸吡咯替尼治疗,经乳腺摄影、上腹部、胸部及头颅CT平扫,后复查肝脏核磁评估治疗效果。结果病人2018年9月复查核磁显示肝S7转移瘤变小,2019年4月复查核磁显示病灶无明显进展。结论马来酸吡咯替尼治疗HER2阳性晚期乳腺癌伴肝转移可能使病人获益。
Objective To explore the clinical efficacy of pyrrolidine maleate in the treatment of human epithelial factor receptor-2(HER2)-positive advanced breast cancer with liver metastases.Methods A patient with HER2-positive advanced breast cancer admitted to The Affiliated Hospital of Hebei University from April 2017 to April 2019 was selected as the study subject.The TCbH regimen(docetaxel+carboplatin+trastuzumab)was given for 6 cycles,followed by CbH(carboplatin+trastuzumab)for 2 cycles.After disease progression(emergence,metastasis),the patient was treated with pyrrolidine maleate,and the efficacy was assessed by mammography,upper abdomen,chest and head CT scan,and magnetic resonance imaging(MRI)of the liver.Results In September 2018,the patient’s MRI reexamination result of the liver showed that the liver S7 metastasis became smaller.In April 2019,MRI reexamination result showed no significant progression.Conclusion Pyrrolidine maleate may benefit patients with HER2-positive advanced breast cancer with liver metastases.
作者
张英
李中
李绿竹
陈鹊汀
ZHANG Ying;LI Zhong;LI Lvzhu;CHEN Queting(Department of Breast Surgery,The Affiliated Hospital of Hebei University,Baoding,Hebei 017000,China)
出处
《安徽医药》
CAS
2021年第2期394-396,共3页
Anhui Medical and Pharmaceutical Journal
关键词
乳腺肿瘤
受体
表皮生长因子
肝转移
马来酸吡咯替尼
Breast neoplasms
Receptor,epidermal growth factor
Liver metastasis
Pyrrolidine maleate
